Format

Send to

Choose Destination
PLoS One. 2016 Dec 1;11(12):e0167146. doi: 10.1371/journal.pone.0167146. eCollection 2016.

Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk.

Author information

1
Medical University of Innsbruck, Department of Medicine II, Gastroenterology and Hepatology, Anichstr. Innsbruck, Austria.
2
Central Institute for Medical and Chemical Laboratory Diagnosis, Innsbruck University Hospital, Anichstr. Innsbruck, Austria.
3
Medical Research Council (MRC) Human Nutrition Research, Elsie Widdowson Laboratories, Fulbourn Road, Cambridge, United Kingdom.
4
Medical University of Innsbruck, Department of Medicine I, Gastroenterology, Endocrinology and Metabolism, Anichstr. Innsbruck, Austria.
5
Medical University of Vienna, Department of Pathology, Währingergürtel, Vienna, Austria.

Abstract

BACKGROUND:

Ferric carboxymaltose (FCM) and iron isomaltoside 1000 (IIM) are increasingly used because they allow correction of severe iron deficiency in a single infusion. A transient decrease in serum phosphate concentrations is a frequent side effect of FCM.

AIM:

To characterize this adverse event and search for its predictors in a gastroenterology clinic patient cohort.

METHODS:

Electronic medical records of patients attending the University Hospital of Innsbruck were searched for the keywords ferric carboxymaltose or iron isomaltoside. Eighty-one patients with documented administration of FCM or IIM with plasma phosphate concentrations before and after treatment were included.

RESULTS:

The prevalence of hypophosphatemia (<0.8 mmol/L) increased from 11% to 32.1% after treatment with i.v. iron. The hypophosphatemia risk was greater after FCM (45.5%) compared with IIM (4%). Severe hypophosphatemia (<0.6 mmol/L) occurred exclusively after FCM (32.7%). The odds for hypophosphatemia after i.v. iron treatment were independently determined by baseline phosphate and the choice of i.v. iron preparation (FCM vs. IIM-OR = 20.8; 95% CI, 2.6-166; p = 0.004). The median time with hypophosphatemia was 41 days, but prolonged hypophosphatemia of ≥ 2 months was documented in 13 of 17 patients in whom follow-up was available. A significant increase in the phosphaturic hormone intact FGF-23 in hypophosphatemic patients shows that this adverse event is caused by FCM-induced hormone dysregulation.

CONCLUSION:

Treatment with FCM is associated with a high risk of developing severe and prolonged hypophosphatemia and should therefore be monitored. Hypophosphatemia risk appears to be substantially lower with IIM.

PMID:
27907058
PMCID:
PMC5131956
DOI:
10.1371/journal.pone.0167146
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center